Effectiveness of Switching CGRP monoclonal antibodies in non-responder 1

2 patients in the UAE: A retrospective study.

- 3 Reem Suliman^{1*}, Vanessa Santos¹, Ibrahim Al Qaissi¹, Batool Aldaher¹, Ahmed Al Fardan¹, Hajir Al
- 4 Barrawy¹, Yazan Bader¹, Jonna Lvn Supena¹, Kathrina Alejandro¹, Taoufik Alsaadi^{1*}
- 5 Affiliations:
- 6 ¹Departemnt of Neurology, American Center for Psychiatry and Neurology, Abu Dhabi, UAE
- 7 *Corresponding authors
- 8 E-mail: Rk.suliman16@gmail.com (RS) Talsaasi@live.ca (TA)

Abstract 9

10

11 Calcitonin gene-related peptide monoclonal antibodies (CGRP mAbs) have shown promising 12 effectiveness in migraine management compared to other preventative treatment options. Currently 13 there are several studies related to the efficacy and tolerability of CGRP mAbs in the management of 14 mgraine. However, many questions remain unanswered when it comes to switching between antibody 15 classes as a treatment option in patients with migraine headaches. The present study seeks to explore 16 and assess the treatment response to CGRP mAb in patients who have previously failed other CGRP

17 mAbs.

18 This was a retrospective, real-world, exploratory study. The participants included within the study were 19 adult (\geq 18 years) patients diagnosed with migraine. Patients who were treated with two or more GCRP 20 mAbs were retrospectively analyzed. Data was collected from one site, 53 patients with migraine 21 headache switched between three CGRP mAb types (Eptinezumab, Erenumab, and Glacanezumb) due 22 to lack of efficacy of the original prescribed CGRP mAb. Efficacy of switching between types of CGRP 23 mAb's was evaluated through documented MMD's in patient diaries and clinical records. Non-24 parametric analysis was used to compare efficacy of the first six months of each prescribed medication. 25 The analysis of efficacy demonstrated that some improvements were seen in both class switch cohorts 26 (CGRP/R to CGRP/L and CGRP/L to CGRP/R). However, the most noticeable improvement in efficacy 27 of the prescription switch was found in patients who switched between different medications of the CGRP/L class. Both chronic migraine and episodic migraine patients showed improved MMD's, 28 29 however chronic migraine patients demonstrated higher responsiveness of efficacy following this lateral 30 switching. The safety of switching between CGRP classes was well observed as any adverse events 31 presented pre- class switch did not lead to the discontinuation of treatment following the later switch. 32

The findings of this study suggest that switching between different classes of CGRP mAbs is a 33 potentially safe and clinically viable practice that may have some applications for those experiencing 34 side effects on their current CGRP mAb or have suboptimal response. This is especially true for patients 35 initiating treatment on ligand targeted CGRP mAb who experience side effects or lack of meaningful 36 efficacy, as the ligand-ligand cohort seems to demonstrate the best outcome. Larger cohort studies and 37 longer follow ups are needed to validate our findings.

- 38
- 39 40
- 41
- NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice. 42

Introduction 43

44

45 Migraine is a neurological disorder experienced by an estimated global point prevalence range of 14,107 46 cases per 100,000 (1). According to the 2019 Global Burden of Disease Study, migraine is the second 47 most common non-fatal disease in terms of "years lived with disability" (2). Those suffering from 48 migraine experience a significant impact on their ability to maintain their productivity and relationships, 49 mandating continuous efforts to better understand its pathophysiology and optimal treatment options 50 (3). Although the precise mechanism of migraine remains unknown, recent findings suggest the 51 calcitonin gene-related peptide (CGRP) plays an integral role (4). Responsible for nociception within 52 the trigeminal ganglion, CGRP represents a major point of intrigue in the development of migraine 53 prophylactic medication. Thus, numerous studies have emerged within the past decade investigating the 54 effectiveness of monoclonal antibodies (mAbs) as CGRP receptor antagonists in migraine treatment.

55

56 Older treatment options for migraine prevention have not been very successful in alleviating the 57 personal and economic burden of migraine (5). A major reason for the lack of success is their limited 58 tolerability and patient adherence (6). Antiepileptics, beta-blockers and antidepressants are examples of 59 these medications. Furthermore, these medications have not been very effective in treating migraine 60 headaches and reducing migraine burden (6).

61

62 On the other hand, mAbs result in better treatment outcomes and, due to their long half-lives, they can 63 be dosed at long intervals, which can be a preferable option for some patients (7). Less frequent dosing 64 can minimize the burden on the patient and assures better treatment adherence. Presently, a small 65 collection of monoclonal antibody medications have been approved for the preventative treatment of episodic and chronic migraine by the U.S. Food and Drug Administration (FDA). Such monoclonal 66 67 antibodies include: Galcanezumab, Eptinezumab and Fremanezumab which target the CGRP ligand 68 and Erenumab which targets CGRP receptors Table 1 (4).

69

70 Recent studies examining usage of Erenumab suggest that it can effectively reduce migraine frequency 71 and improve quality of life (8). In a similar study assessing the efficacy and tolerability of Erenumab 72 among 418 patients, 168 (69.7 %) reported that the benefits of Erenumab outweighed any potential 73 drawbacks (9). Episodic migraine patients with at least one previous preventative treatment failure 74 (PPTF) exhibited significantly greater gains in efficacy compared to placebo (10). Among the 75 aforementioned mAbs, Eptinezumab stands out as the sole drug capable of intravenous administration, 76 allowing for a rapid onset of action (11). This unique quality allows for quicker headache pain relief 77 (12), and reduced monthly migraine days compared to placebo (13). Similarly, the effectiveness of 78 Galcanezumab was well established for patients with episodic and chronic migraines (14). Existing 79 literature on CGRP monoclonal antibodies (CGRP mAbs) suggests high patient tolerability;

80 discontinuation is most commonly attributed to lack of efficacy rather than adverse effects (15). Despite 81 a lack of major differences in efficacy across clinical trials, a few case series studies found some patients 82 who have suboptimal response to one mAb has managed to successfully switch to another one with 83 noted significant improvements (16–19). One real-world analysis study demonstrated that one-third of 84 Erenumab non-responders achieved >30% response after switching to another CGRP-mAb (20). 85 86 These findings warrant further investigation into the efficacy and safety of switching between CGRP-87 mAb classes. Therefore, this study will investigate the treatment effectiveness, tolerability, and

88 adherence of migraine patients in the United Arab Emirates (UAE) following a switch from a PPTF to 89 another mAb. This study will serve as an integral step toward advancing our understanding of migraine 90 treatment. It shall also represent the first of its kind by focusing on an underrepresented population in 91 clinical research.

- 92
- 93

95

94 Table 1: CGRP Targeting drugs.

Drug	Mechanism	Indication	Dosing	FDA Approved	Availability in the UAE
Erenumab	Blocks CGRP receptor	Prophylactic	Monthly, subcutaneous	2018	Yes
Eptinezumab	Binds to CGRP ligand	Prophylactic	Quarterly, intravenous	2020	Yes
Glacanezumab	Binds to CGRP ligand	Prophylactic	Monthly, subcutaneous	2018	Yes
Fremanezumab	Binds to CGRP ligand	Prophylactic	Monthly or quarterly, subcutaneous, but intravenous load for cluster headache	2018	No

96

97

Methods 98

Study Design 99

100 This was a retrospective, real-world exploratory study. Data used was gathered from one site, The 101 American Center for Psychiatry and Neurology (ACPN), Abu Dhabi, UAE. A total of 391 patients with 102 episodic migraine (EM) or chronic migraine (CM) who have received at least one dose of GCGRP/R 103 mAb (Erenumab), or CGRP/L mAb (Eptinezumab, or Glacanezumab) were reviewed for eligibility to 104 be included in the study. Fremanezumab is currently not available in the UAE, therefore it has not been 105 included in the analysis. 106

107 Data was gathered from patient's clinical records which contain all the required demographic 108 information, diagnosis, medication history, Monthly Migraine Day (MMD) at baseline and at follow up 109 visits. Additionally, patient satisfaction with medication was documented in their clinical records. 110 Patients were asked to keep a record of attacks and symptoms in their headache diaries. Efficacy of the 111 prescribed treatment was evaluated by measuring the change in MMD between visits. Safety was also 112 assessed; this was done by monitoring adverse events.

113

Follow-up visits were scheduled monthly or as deemed necessary, which is a standard protocol at our site for all patients initiating treatment on mAbs. Patients were assessed on their baseline frequency of MMDs and, subsequently, thorough discussions with treating physician on which mAb would be most effective, addressing each patients' specific needs. If the current medication did not result in any meaningful reduction of MMDs, an option to switch to another mAb was offered to the patient.

119

The retrospective analysis mainly focused on two main periods. The first period included data of patients treated with a specific CGRP mAb, while the second period involved data on patients who switched to another anti CGRP mAb. Switching was mainly due to lack of efficacy; it was ensured that patients included in the analysis completed at least 3 months of treatment before switching. During each phase, patients' MMDs were assessed at 3 stages prior to and following their medication switch: at least

- 125 one month before the first injection (baseline), at a 3-month follow-up, and at a 6-month follow-up.
- 126

127 Ethics

128

This study was conducted in accordance with the Helsinki Declaration of 1964 and consistent with Good Clinical Practice (GCP). All ethical guidelines, health authority regulations and data privacy laws were ensured. Prior to the start of the study all relevant approvals were obtained from ACPNs Institutional Review Board (IRB), a waiver of informed consent from the corresponding ethics committee was obtained. To ensure transparency and accuracy all authors were given access to the study data.

135

136 Sample

137

Records from ACPNs nursing department were gathered where all patients who have been administered one mAb have been screened and identified (Figure 1). Data included patients from January 2018 up to September 2022, who are adults (≥18 years), and who had a diagnosis of either EM or CM, as per the International Classification of Headache Disorders (ICHD-3) criteria. Data was shared independent of treatment effects or cause for the GGRP mAb switch.

143 Patients were included in the analysis if they (i) switched between two of the previously mentioned 144 CGRP mAbs (switchers) (ii) received at least three doses of the first CGRP mAb and maintained 145 treatment for a minimum of 6 month after switching. Those who have demonstrated a meaningful 146 response, which is defined as more than 50% reduction in MMD for EM, and more than 30% for CM, and were 147 satisfied with their treatment remained on their current preventative treatment hence they were not 148 included in the effectiveness analysis. Patients were categorized according to their switching profiles. 149 The three profiles represented were: CGRP/R mAb to GCRP/L mAb, CGRP/L to CGRP/R, or CGRP/L 150 to another CGRP/L mAb (Fig 1).

151

153

Variables, data extraction, and endpoints 152

154 The number of MMDS were extracted from the headache diaries as documented on the patients' 155 electronic medical record (EMR). Due to the non-standardized headache diaries and the varying details 156 of documentation of headache characteristics and accompanying symptoms during each headache 157 attack, reliable differentiation between headache and migraine days was not possible. The primary 158 endpoint was the absolute change from baseline in MMDs response rate (>25%, >50%, >75%, and 159 100% reduction in MMDs) of each category of the switchers. As per the methodology outlined by 160 Kaltseis et al. in 2023, patients who demonstrated a positive response to treatment were classified as 161 responders. This was determined by a minimum reduction of 50% in MMDs for EM or a minimum 162 reduction of 30% in MMDs for CM after receiving treatment for a minimum of 3 months. Patient 163 characteristics including age, gender, migraine diagnoses, migraine years, and type of CGRP-mAb from 164 the EMR.

- 165
- 166

Objectives 167

168

169 The primary objective was to retrospectively assess the reduction in frequency of migraines and 170 determine the efficacy of the current preventative treatment following the switch from a previous CGRP 171 mAb. Additionally, the study sought to evaluate the tolerability of the treatment and report any adverse 172 reactions.

173

Statistical Analysis 174

175 Since this analysis was conducted retrospectively the sample size was not based on any statistical 176 consideration. The sample size was achieved depending on the number of cases fulfilling the inclusion 177 criteria treated at ACPN. Continuous variables were summarized using mean ± standard deviation [SD] 178 or median interquartile range [IQR], while categorical data were presented as numbers and percentages. 179 The normality assumption was evaluated using the Shapiro-Wilk test. Given that the data did not follow 180 a normal distribution, the Wilcoxon signed-rank test was used to analyze the changes in quantitative 181 variables pre-post changes. A significance level of p < 0.05 was considered statistically significant for

all variables. The statistical software SPSS version 26.0 (IBM Corp. SPSS Statistics, Armonk, NY,

- 183 USA) was utilized for all data analyses.
- 184

185 **Results**

186 Demographic and Baseline Characteristics

The participant pool was composed of 53 individuals; all of whom had undergone a switch from one CGRP mAb to another; the descriptive statistics for this cohort are visualized in **Table 2**. Among the 53 participants, 42 (79.2%) of whom were female, 20 (37.7%) were diagnosed with CM while the remaining 33 (62.3%) were diagnosed with EM. The mean age (SD) of participants in years was 39.2

- 191 (11.0). Furthermore, patients were categorized according to their switching profile, they had the
- 192 following distribution CGRP/L to R mAb (n=11; 20.7%), CGRP/R to L mAb (n=24; 45.3%), and
- 193 CGRP/L to L mAb (n=18; 34.0%).
- 194 Out of the 53 patients, 16 individuals had previously attempted preventative treatment for migraine.

195 One patient has tried two preventative therapies before switching to a CGRP mAb, while the remaining

196 15 only had one preventative treatment failure prior to switching. Previous preventative treatments

- 197 included: Propranolol, Amitriptyline, Flunarizine, Topiramate, and OnabotulinumtoxinA Table 2.
- 198

200

199 Table 2: Patient demographics and clinical features

	Total Cohort (n=53)
Demographics	
Âge (years), mean +/- SD.	39.2 +/-11.0
Sex female, n (%)	42 (79.2%)
Migraine features	
Chronic Migraine, n (%)	20 (37.7%)
Patients with daily headaches, n (%)	10 (18.9%)
Age at Migraine Diagnosis, mean +/- SD	27.56 +/- 10.62
Migraine duration (years), mean +/- SD	11.6 +/- 11.3
Other features	
Positive family history of migraine, n (%)	16 (30%)
Received prior preventive treatment, n (%)	16 (30%)
Psychiatric comorbidity, n (%)	24 (45.0%)
Previous Preventative Class Failures	
2 classes, n (%)	1 (1.8%)
1 class, n (%)	15 (28.3%)
Drug Classes	
Beta-blockers, n (%)	1 (1.8%)
Tricyclic antidepressant, n (%)	8 (15.1%)
Calcium channel blockers, n (%)	3 (5.7%)
Anticonvulsants, n (%)	2 (3.8%)
OnabotulinumtoxinA, n (%)	3 (5.7%)
First monoclonal antibody	

CGRP/L mAb, n (%)	29(55.0%)
Galacanezumab, n (%)	28 (53)
Eptinezumab, n (%)	1(2.0%)
CGRP/R mAb (erenumab), n (%)	24 (45.0%)
Second monoclonal antibody	
CGRP/L mAb, n	42
Galacanezumab, n	7
Eptinezumab, n	35
CGRP/R mAb (erenumab), n	11
Switching Profile	
CGRP/L to $CGRP/R$, n	11
CGRP/L to another CGRP/L, n	18
CGRP/R to $CGRP/L$, n	24

212

213 Throughout the study, the frequency of participants' monthly migraine days (MMD) was assessed at 3 214 stages prior and following their medication switch: at baseline, at a 3-month follow-up, and a 6-month 215 follow-up, this can be visualized in Fig 2. As exhibited in Table 3, the greatest mean (SD) MMD values 216 were recorded at the baseline assessments; however, it is worth mentioning that the post-switch baseline 217 mean of 10.21 (5.42) was lower than that of the pre-switch baseline mean of 12.92 (8.23). Following 218 the pre-switch baseline assessment, the mean was reduced to 5.53 (5.73) by month 3, however it rose 219 slightly to 5.92 (6.69) by month 6. Following the post-switch baseline assessment, mean MMD dropped 220 to 5.74 (4.32) by month 3 further decreased to 5.42 (4.98) by month 6.

221

222

223 **Table 3: MMD Mean Data Pre- and Post-Switch**

Variable	Mean	Minimum	Maximum	Standard Deviation
Pre-switch BL	12.02	1.0	20.0	0.22
MMD Pre-switch M3	12.92	1.0	28.0	8.23
MMD	5.53	0.0	28.0	5.73
Pre-switch M6 MMD	5.92	0.0	28.0	6.69
Post-switch BL	10.21	2.0	20.0	5.40
MMD Post-switch M3	10.21	2.0	28.0	5.42
MMD	5.74	0.0	15.0	4.32
Post-switch M6 MMD	5.42	0.0	28.0	4.98

²²⁴

First anti-CGRP monoclonal antibody 226

227 A total of 29 patients were initiated on CGRP/L mAbs, while 24 patients were started on CGRP/R 228 mAbs. Upon conducting a follow-up at month 3, it was observed that patients with CM exhibited a

²²⁵

higher response rate as compared to patients with EM. Specifically, 72% of CM patients responded to
treatment with CGRP/L mAb, whereas 100% of CM patients responded to CGRP/R mAb. On the other
hand, 61% and 63% of EM patients responded to CGRP/L mAb and CGRP/R mAb respectively.
However, it is worth noting that the CM group displayed higher rates of non-responsiveness when

treated with CGRP/L mAb (27%) as opposed to CGRP/R mAb (0%). Upon analyzing the 6-month

- 234 follow-up data, no significant improvement in response rates was observed. Notably, 8 EM patients
- remained non-responders to both classes of CGRP-mAb. Further details regarding response rates during
- the initial observational period on the first medication are displayed on Fig 3.
- 237

238 Second anti-CGRP monoclonal antibody

239 During the second observational period, the 24 patients who received CGRP/R-mAb as their first 240 CGRP- mAbs switched to anti-CGRP/L-mAbs (7 Galcanezumab and 17 Eptinezumab), whereas out of 241 the 29 patients who started on CGRP/L-mAb (28 Galcanezumab and 1 Eptinezumab), 11 patients were 242 switched to CGRP/R-mAbs (Erenumab) and 18 patients to another class of CGRP/L-mAb 243 (galcanezumab). All the patients in the latter group have switched from Galcanezumab to Eptinezumab, 244 while the one patient who initially received Eptinezumab was switched to Erenumab. Surprisingly, 245 response rates during the second observational period at month 3 follow-up dropped in the CM and EM 246 patients who were switched from CGRP/R-mAbs to CGRP/L-mAbs, from 100% and 63% to 71% and 247 41% respectively, (Fig 3b and 4a). On the other hand, CM patients who started on CGRP/L-mAb, had 248 a higher response rate when they were switched to another anti-CGRP/L-mAb (100%) than to anti-249 CGRP/R-mAb (87.5%) at month 3, (Fig 4b and 4c). Overall, CM had a better response rate than EM 250 during the second observational period Fig 4.

251

252 First vs Second anti-CGRP monoclonal antibody

Table 4 and table 5 present the median differences in MMDs at 6 months compared to the baseline.
These tables specifically focus on the first and second CGRP mAbs administered to different patient
groups. Interestingly, the overall reduction in MMDs for all patients is precisely identical for both the
first and second mAbs.

- 257
- 258

259 Table 4: Changes in MMD during first CGRP mAb from 1st baseline.

	<i>Median difference</i> (IQR) 6 Month	N
All patients	-5.1 (5.5)	53
P-value	0.000	

Anti-CGRP/L before switching to anti CGRP/R	-2.2 (7.0)	11
P-value	0.025	
Anti-CGRP/R before switching to anti CGRP/L	-3.15 (4.5)	24
P-value	0.002	
Anti-CGRP/L before switching to another anti-CGRP/L	-3.21 (5.25)	18
P-value	0.001	
IQR, Interquartile range		

²⁶⁰

261

262

 Table 5: Changes in MMD during second CGRP mAb from 2nd baseline

	Median difference	
	(IQR) 6 Month	Ν
All patients	-5.0 (5.0)	53
P-value	0.000	
Anti CGRP/R after Anti CGRP/L	-1.60 (9.0)	11
P-value	0.109	
Anti-CGRP/L after CGRP/R	-3.73 (3.75)	24
P-value	0.000	
Anti-CGRP/L after another anti-CGR	PP/L -3.47 (7.25)	18
P-value	0.001	

263

264

265 Documented in Table 6, patients were assessed on their reduction in MMDs from the 6-month follow-266 up pre-switch to their 6-month follow-up post-switch as an additional evaluation of treatment efficacy 267 following a medication switch. In line with the results of the Wilcoxon tests, among ligand-receptor 268 switchers, only 1 (11.1%) participant experienced a greater than 50% reduction in MMDs, while the 269 vast majority (66.7%) experienced less than 25% reduction. Although a greater proportion of receptor-270 ligand switchers (19.1%) experienced greater than 50% reduction on MMDs, an overwhelming majority 271 (71.4%) experienced less than 25% reduction. Interestingly, the ligand-ligand cohort exhibited the 272 greatest proportion (33.4%) of participants experiencing greater than 50% reduction, and the lowest 273 proportion (44.4%) of those experiencing less than 25% reduction.

274

275 Table 6: M6-M6 Percent Reductions

	Switching Profile	Q1 frequency (%)	Q2 frequency (%)	Q3 frequency (%)	Q4 frequency (%)
	Ligand-Receptor	6.0 (66.7)	2.0 (22.2)	0.0 (0.0)	1.0 (11.1)
	Receptor-Ligand	15.0 (71.4)	2.0 (9.5)	1.0 (4.8)	3.0 (14.3)
	Ligand-Ligand	8.0 (44.4)	4.0 (22.2)	3.0 (16.7)	3.0 (16.7)
276	<i>Q1: <25% reduction in MMD, Q2</i>	: 25% <x<50% in<="" reduction="" th=""><th>MMD, Q3: 50%<x<75%< th=""><th>reduction in MMD, Q4: ></th><th>75% reduction in MMD</th></x<75%<></th></x<50%>	MMD, Q3: 50% <x<75%< th=""><th>reduction in MMD, Q4: ></th><th>75% reduction in MMD</th></x<75%<>	reduction in MMD, Q4: >	75% reduction in MMD
277					

278

279 Exposure and Safety

280 In this particular study, a total of 53 patients were included. Out of these patients, it was observed that 281 4 individuals had an adverse event (AE), 3 of which took place prior to the switch in treatment. 282 However, it is important to mention that despite these AEs, these patients did not opt to discontinue the 283 treatment, indicating that the AEs were of a minor nature. AEs included constipation, slight pain on 284 injection site, and increased itchiness. The remaining patient reported an AE after the switch. This 285 particular AE involved peri labial numbress and swelling, which occurred during the infusion. The 286 patient was closely monitored and subsequently discharged safely. Treatment was well-tolerated among 287 the remaining 49 patients.

288 289

290 Discussion

291 Despite the recent growth in CGRP-mAb use as a unique migraine treatment strategy, relatively little 292 is known regarding how switching between CGRP-mAb classes can impact the efficacy and tolerability 293 of treatment. Therefore, this study represents another step in furthering our understanding of how 294 CGRP-mAb treatments can be safely and effectively applied in a clinical context. Moreover, to our 295 knowledge, this is the first real-world study of its kind to be conducted in the United Arab Emirates and 296 GCC region, including, this underrepresented population, from the pivotal trials. Determined prior to 297 data analysis, our primary endpoint was to determine the impact, if any, of switching between CGRP-298 mAb medications on the effectiveness of MMD reduction. Furthermore, our secondary endpoint was to 299 assess the safety and tolerability associated with that switching.

300

301 The 53 patients included in data analysis were classified according to their switching profile including: 302 switching from receptor-targeted to ligand-targeted treatment (RL), from ligand-targeted to ligand-303 targeted (LL) treatment, and from ligand-targeted to receptor-targeted (LR) treatment. Using a 304 Wilcoxon Signed Ranks Test, groups were compared at baseline (BL), month 3 (M3), and month 6 305 (M6) stages to assess if changes in MMDs were attributable to treatment. Although RL and LL patients 306 experienced significant reductions in MMD between BL and M6 after switching, this was not the case 307 for LR patients. This incongruence between groups warrants further investigation, with larger cohorts, 308 into the pathophysiology of CGRP-mAb treatments to explain why switching in one direction produces 309 starkly different outcomes than the other.

310 Indeed, prior to conducting the study, we expected switching between different classes of CGRP mAbs

311 would yield improved results, especially for those switching from L to R or vice versa. However, to our

312 surprise, our results showed that switching from ligand to ligand produced better outcomes. This

313 unexpected finding underscores the importance of studying the mechanism of CGRP mAb treatments

in greater detail. Conducting future studies with larger cohorts would provide a better insight into the

315 pathophysiology of these treatments and may help further understand why switching from ligand to 316 ligand produces a better outcome.

317

318 Despite a lack of statistically significant difference between M6 values pre- and post-switching, we 319 found it valuable to quantify the percent MMD reduction according to switching profile. Notably, 33.4% 320 of LL patients experienced at least 50% reduction in MMDs 6 months post-switch, when compared to 321 their 6-month data from their initial medication. Among LR and RL patients, less than 20% of each 322 group experienced a similar degree of MMD reduction. These findings offer modest support to the 323 notion that considering drug mechanism of action may lend itself to improved outcomes post-switching. 324 Unfortunately, as Erenumab is the only drug included targeting CGRP receptors, there is no means of 325 assessing a receptor-receptor switch for a similar phenomenon.

326

On the topic of safety, 3 of 4 documented AEs took place prior to switching, all of which were considered mild and did not impact patients' continuation on treatment. It is worth noting that despite experiencing AEs on their previous CGRP-mAb treatment, the aforementioned 3 patients switching to another mAb did not result in worsening or new AEs. This is a promising development pointing to switching being as a safe, tolerable, and, probably, effective process for those experiencing side effects with their first CGRP-mAb prescription.

333

We have identified two retrospective studies examining lateral switching between CGRP mAb therapies (20,21), to serve as points of comparison of our findings relative to those in the existing literature. The study by Overeem et al. (20) conducted a real-world, multicentre analysis of 78 patients with PPTF on erenumab (receptor-targeted therapy) who switched to ligand-targeted therapies. Unlike the 50 % meaningful response rate that was used in our study, their analysis yielded >30% reduction in MHDs by month 3 after switching in 32% of patients and >50% reduction in 12% of patients.

On the other hand, the study by Kaltseis et al. (20,21), conducted a larger retrospective assessment of 171 who received either one, two, or three different anti-CGRP mAbs. In contrast to the study by Overeem et al., non-response was set at <50% reduction in MMDS in EM patients, and <30% reduction in CM patients. (5.3%) of participants discontinued due to negative side effects. As compared to our study, that study was heavily focused on the quantity of PPTFs. Our study, however, has carefully analysed, the impact of switching directionality on outcomes.

346

In addition, and in contrast to the study by Overeem et al (20), where patients who switched from
CGRP/R mAb to any CGRP/L mAb experienced improved MMDs, our study did not observe similar
outcomes, which could be due to the different characteristics of our cohorts as compared to theirs.

350 Indeed, our cohorts included 37 naïve patients who have not previously tried other preventive therapies,

representing, probably, less refractory patients than those previously studied in the literature. Out of the
53 patients in our cohorts, 16 individuals had previously attempted preventative treatment for migraine.

353

354 Limitations

355

356 Our study had several limitations that must be acknowledged. Being retrospective in nature means that 357 controlling certain variables that may have affected the results was not possible. Additionally, the 358 sample size included was small, which limits the generalizability of our findings. As a result, it is worth 359 noting that the data analyzed involved one patient who was initially on Eptinezumab who have switched 360 to Glacanezumab, and consequently further studies may be required to confirm our findings on Ligand-361 Ligand lateral switching outcomes following similar direction of switching, and to verify the 362 generalizability of the data. Furthermore, the effectiveness outcome was solely based on MMD 363 reduction. Thus, it may not fully capture the impact of the intervention on other patient related 364 outcomes. Due to the relatively short observation period of six months for both first and second 365 medication, it is not possible to rule out the potential for further improvement that could have been 366 attained if patients had prolonged their use of the initial medication before switching to an alternative 367 one. However, the recent European Headache Federation (EHF) guidelines have suggested 3 months 368 of observation is sufficient to assess the effectiveness of mAbs (22). Finally, it is important to 369 acknowledge the differences in regulation of prescribing mAbs in UAE as compared to other parts of 370 the world. It is worth noting that currently in UAE there exists no prerequisite for individuals to have 371 undergone a specific number of unsuccessful preventative treatment prior to being administered a 372 CGRP mAb, which make our studied cohorts unique in that regards.

373

374 Conclusion

This retrospective, real-world exploratory study examining the effectiveness and safety of switching between CGRP-mAb treatments serves as an essential step into furthering our understanding of an under-researched topic. The findings of this study suggest that the outcome of switching from a previous treatment does not significantly influence the outcome of future prescriptions' effectiveness nor safety.

Among 53 patients enrolled, none experienced significant changes in their MMD when comparing their mean data 6 months on the previous medication against 6 months on the new medication. Nevertheless, the data suggests that those switching from one ligand-targeted treatment to another ligand-targeted treatment were more likely to experience additional or compounded reductions in MMD on top of improvements gained from their initial prescription.

385

- 386 Overall, the findings present in this study point to CGRP-switching as a potentially safe and clinically
- 387 viable practice that may have applications for those experiencing suboptimal response on their current
- 388 CGRP-mAb. Further research is warranted to better understand the long-term implications of switching
- 389 beyond a 6-month period, as well as if those switching to a CGRP-mAb of the same class are truly
- 390 likely to experience greater improvements than their counterparts.
- 391
- 392

393 **References:**

- 394
- 395 1. Safiri S, Pourfathi H, Eagan A, Mansournia MA, Khodayari MT, Sullman MJM, et al. 396 Global, regional, and national burden of migraine in 204 countries and territories, 1990 to 397 2019. Pain [Internet]. 2022 Feb [cited 2023 Apr 25];163(2):e293-309. Available from: 398 https://journals.lww.com/10.1097/j.pain.000000000002275
- 399 2. on behalf of Lifting The Burden: the Global Campaign against Headache, Steiner TJ, 400 Stovner LJ, Jensen R, Uluduz D, Katsarava Z. Migraine remains second among the 401 world's causes of disability, and first among young women: findings from GBD2019. J 402 Headache Pain [Internet]. 2020 Dec [cited 2023 Apr 25];21(1):137, s10194-020-01208-403 0. Available from:
- 404 https://thejournalofheadacheandpain.biomedcentral.com/articles/10.1186/s10194-020-405 01208-0
- 406 3. Buse DC, Scher AI, Dodick DW, Reed ML, Fanning KM, Manack Adams A, et al. Impact 407 of Migraine on the Family: Perspectives of People With Migraine and Their 408 Spouse/Domestic Partner in the CaMEO Study. Mayo Clin Proc [Internet]. 2016 May 409 [cited 2023 Apr 25]:91(5):596–611. Available from:
- 410 https://linkinghub.elsevier.com/retrieve/pii/S0025619616001269
- 411 4. Wattiez AS, Sowers LP, Russo AF. Calcitonin gene-related peptide (CGRP): role in 412 migraine pathophysiology and therapeutic targeting. Expert Opin Ther Targets [Internet]. 413 2020 Feb 1 [cited 2023 Apr 25];24(2):91–100. Available from: 414 https://www.tandfonline.com/doi/full/10.1080/14728222.2020.1724285
- 415 5. Edvinsson L, Haanes KA, Warfvinge K, Krause DN. CGRP as the target of new migraine 416 therapies — successful translation from bench to clinic. Nat Rev Neurol [Internet], 2018 417 Jun [cited 2023 Jul 13];14(6):338-50. Available from: 418 https://www.nature.com/articles/s41582-018-0003-1
- 419 6. Schuster NM, Rapoport AM. New strategies for the treatment and prevention of primary 420 headache disorders. Nat Rev Neurol [Internet]. 2016 Nov [cited 2023 Jul 421 13];12(11):635–50. Available from: https://www.nature.com/articles/nrneurol.2016.143
- 422 7. Raffaelli B, Reuter U. The Biology of Monoclonal Antibodies: Focus on Calcitonin Gene-423 Related Peptide for Prophylactic Migraine Therapy. Neurotherapeutics [Internet]. 2018 424 Apr [cited 2023 Jul 13];15(2):324–35. Available from: 425 http://link.springer.com/10.1007/s13311-018-0622-7
- 426 8. Tepper SJ, Ashina M, Reuter U, Brandes JL, Doležil D, Silberstein SD, et al. Long-term safety and efficacy of erenumab in patients with chronic migraine: Results from a 52-427 428 week, open-label extension study. Cephalalgia [Internet]. 2020 May [cited 2023 Apr

- 429 25];40(6):543–53. Available from:
- 430 http://journals.sagepub.com/doi/10.1177/0333102420912726
- 431 9. Kanaan S, Hettie G, Loder E, Burch R. Real-world effectiveness and tolerability of
 432 erenumab: A retrospective cohort study. Cephalalgia [Internet]. 2020 Nov [cited 2023
 433 Apr 25];40(13):1511–22. Available from:
- 434 http://journals.sagepub.com/doi/10.1177/0333102420946725
- 10. Ruff DD, Ford JH, Tockhorn-Heidenreich A, Stauffer VL, Govindan S, Aurora SK, et al.
 Efficacy of galcanezumab in patients with episodic migraine and a history of preventive
 treatment failure: results from two global randomized clinical trials. Eur J Neurol
 [Internet]. 2020 Apr [cited 2023 Apr 25];27(4):609–18. Available from:
- 439 https://onlinelibrary.wiley.com/doi/10.1111/ene.14114
- 440 11. Dhillon S. Eptinezumab: First Approval. Drugs [Internet]. 2020 May [cited 2023 Apr
 441 25];80(7):733–9. Available from: http://link.springer.com/10.1007/s40265-020-01300-4
- Winner PK, McAllister P, Chakhava G, Ailani J, Ettrup A, Krog Josiassen M, et al. Effects
 of Intravenous Eptinezumab vs Placebo on Headache Pain and Most Bothersome
 Symptom When Initiated During a Migraine Attack: A Randomized Clinical Trial. JAMA
 [Internet]. 2021 Jun 15 [cited 2023 Apr 25];325(23):2348. Available from:
 https://jamanetwork.com/journals/jama/fullarticle/2781053
- 13. Dodick DW, Goadsby PJ, Silberstein SD, Lipton RB, Olesen J, Ashina M, et al. Safety
 and efficacy of ALD403, an antibody to calcitonin gene-related peptide, for the
 prevention of frequent episodic migraine: a randomised, double-blind, placebocontrolled, exploratory phase 2 trial. Lancet Neurol [Internet]. 2014 Nov [cited 2023 Apr
 25];13(11):1100–7. Available from:
- 452 https://linkinghub.elsevier.com/retrieve/pii/S1474442214702091
- 453 14. Martin V, Samaan KH, Aurora S, Pearlman EM, Zhou C, Li X, et al. Efficacy and Safety
 454 of Galcanezumab for the Preventive Treatment of Migraine: A Narrative Review. Adv
 455 Ther [Internet]. 2020 May [cited 2023 Jul 21];37(5):2034–49. Available from:
 456 https://link.springer.com/10.1007/s12325-020-01319-9
- 457 15. Alex A, Vaughn C, Rayhill M. Safety and Tolerability of 3 CGRP Monoclonal Antibodies
 458 in Practice: A Retrospective Cohort Study. Headache J Head Face Pain [Internet]. 2020
 459 Nov [cited 2023 Apr 25];60(10):2454–62. Available from:
 460 https://onlinelibrary.wiley.com/doi/10.1111/head.13956
- 461 16. López Moreno Y, Castro Sánchez MV, García Trujillo L, Serrano Castro PJ. Fracaso de 462 un anticuerpo monoclonal anti-CGRP en el tratamiento de la migraña. ¿Tiene sentido 463 probar otro? Rev Neurol [Internet]. 2022 [cited 2023 Apr 25];75(04):87. Available from: 464 https://www.neurologia.com/articulo/2021526
- 465
 465
 466
 466
 467
 468
 468
 468
 469
 469
 469
 460
 460
 461
 462
 463
 464
 465
 465
 465
 466
 466
 467
 468
 468
 468
 469
 469
 469
 469
 469
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
- 18. Patier Ruiz I, Sánchez-Rubio Ferrández J, Cárcamo Fonfría A, Molina García T. Early
 Experiences in Switching between Monoclonal Antibodies in Patients with
 Nonresponsive Migraine in Spain: A Case Series. Eur Neurol [Internet]. 2022 [cited 2023
 Apr 25];85(2):132–5. Available from: https://www.karger.com/Article/FullText/518899

- 474 19. Ziegeler C, May A. Non-Responders to Treatment With Antibodies to the
- CGRP-Receptor May Profit From a Switch of Antibody Class. Headache J Head Face 475
- 476 Pain [Internet]. 2020 Feb [cited 2023 Apr 25];60(2):469–70. Available from:
- 477 https://onlinelibrary.wiley.com/doi/10.1111/head.13729
- 478 20. Overeem LH, Peikert A, Hofacker MD, Kamm K, Ruscheweyh R, Gendolla A, et al. 479 Effect of antibody switch in non-responders to a CGRP receptor antibody treatment in 480 migraine: A multi-center retrospective cohort study. Cephalalgia [Internet]. 2022 Apr
- 481 [cited 2023 Apr 25]:42(4–5):291–301. Available from:
- 482 http://iournals.sagepub.com/doi/10.1177/03331024211048765
- 483 21. Kaltseis K, Filippi V, Frank F, Eckhardt C, Schiefecker A, Broessner G. Monoclonal 484 antibodies against CGRP (R): non-responders and switchers: real world data from an 485 austrian case series. BMC Neurol [Internet]. 2023 Apr 28 [cited 2023 Jun 12];23(1):174. 486 Available from: https://bmcneurol.biomedcentral.com/articles/10.1186/s12883-023-487 03203-9
- 22. Sacco S. Amin FM, Ashina M, Bendtsen L, Deligianni CI, Gil-Gouveia R, et al, European 488 489 Headache Federation guideline on the use of monoclonal antibodies targeting the 490 calcitonin gene related peptide pathway for migraine prevention – 2022 update. J 491 Headache Pain [Internet]. 2022 Dec [cited 2023 Jun 22];23(1):67. Available from: 492 https://thejournalofheadacheandpain.biomedcentral.com/articles/10.1186/s10194-022-493 01431-x

494

Table 1: CGRP Targeting drugs

	Drug	Mechanism	Indication	Dosing	FDA Approved	Availability in the UAE
	Erenumab	Blocks CGRP receptor	Prophylactic	Monthly, subcutaneous	2018	Yes
	Eptinezumab	Binds to CGRP ligand	Prophylactic	Quarterly, intravenous	2020	Yes
	Glacanezumab	Binds to CGRP ligand	Prophylactic	Monthly, subcutaneous	2018	Yes
medRxiv pro preprint (wh		1/ 1823 nd 0412329365 R this v review) is the author/funder, w perpetuity. de available under a CC-BY 4.		3. The convignt holder or this arterly, icense to display the preprint in subcutaneous, but intravenous load for cluster headache	2018	No

Table 2: Patient demographics and clinical features

	Total Cohort
	(n=53)
Demographics	
Age (years), mean +/- SD.	39.2 +/-11.0
Sex female, n (%)	42 (79.2%)
Migraine features	
Chronic Migraine, n (%)	20 (37.7%)
Patients with daily headaches, n (%)	10 (18.9%)
Age at Migraine Diagnosis, mean +/- SD	27.56 +/- 10.62
int doi: https://dv/org/19-11/01/2029/08/05 08/29065/11 this version posted August 8, 2028. The copyright h was not certified by peer review is the author/funder, who has granted medRxiv a license to display	holder for this 1.6 +/- 11.3
perpetuity. Other features available under a CC-BY 4.0 International license .	
Positive family history of migraine, n (%)	16 (30%)
Received prior preventive treatment, n	16 (30%)
(%)	24 (45.0%)
Psychiatric comorbidity, n (%)	
Previous Preventative Class Failures	
2 classes, n (%)	1 (1.8%)
1 class, n (%)	15 (28.3%)
Drug Classes	
Beta-blockers, n (%)	1 (1.8%)
Tricyclic antidepressant, n (%)	8 (15.1%)
Calcium channel blockers, n (%)	3 (5.7%)
Anticonvulsants, n (%)	2 (3.8%)
OnabotulinumtoxinA, n (%)	3 (5.7%)
First monoclonal antibody	
CGRP/L mAb, n (%)	29(55.0%)
Galacanezumab, n (%)	28 (53)
Eptinezumab, n (%)	1(2.0%)
CGRP/R mAb (erenumab), n (%)	24 (45.0%)
Second monoclonal antibody	
CGRP/L mAb, n	42
Galacanezumab, n	7
Eptinezumab, n	35
CGRP/R mAb (erenumab), n	11
Switching Profile	
CGRP/L to CGRP/R, n	11
CGRP/L to another CGRP/L, n	18
	24

Table 3: MMD Mean Data Pre- and Post-Switch

V	ariable	Mean	Minimum	Maximum	Standard Deviation
	switch BL MMD	12.92	1.0	28.0	8.23
1	switch M3 MMD	5.53	0.0	28.0	5.73
1	switch M6 MMD	5.92	0.0	28.0	6.69
	switch BL MMD	10.21	2.0	28.0	5.42
		3.08.04.23293651; this version postec w) is the author/funder, who has grant perpetuity. ailable under a CC-BY 4.0 Internationa	August 8, 2023. The copyright holde ed medRxiv a license to display the p al license .	er for this preprint in 15.0	4.32
	switch M6 MMD	5.42	0.0	28.0	4.98

	Median difference (IQR)		
	6 Month	Ν	
All patients	-5.1 (5.5)	53	
P-value	0.000		
Anti-CGRP/L before switching to anti CGRP/R	-2.2 (7.0)	11	
P-value	0.025		
Anti-CGRP/R before	-3.15 (4.5)	24	
switching to anti CGRP/L			
P-value	nis version posted August 8, 2023. The copyright holder for this		
(which was not contified by peer review) is the author/fund before It is made available under a CC-B	nis version posted August 8, 2023. The copyright holder for this er, who has granted medRxiv a license to display the preprint in y. Y 4.0 International license .	18	
P-value	0.001		

Table 4: Changes in MMD during first CGRP mAb from 1st baseline.

Table 5: Changes in MMD during second CGRP mAb from 2nd baseline

	Median difference	
	(IQR)	
	6 Month	Ν
All patients	-5.0 (5.0)	53
P-value	0.000	
Anti CGRP/R after Anti CGRP/L	-1.60 (9.0)	11
P-value	0.109	
Anti-CGRP/L after CGRP/R	-3.73 (3.75)	24
P-value	0.000	
Anti-CGRP/L after another anti-CGR	P/L -3.47 (7.25)	18
P-value	0.001	

medRxiv preprint doi: https://doi.org/10.1101/2023.08.04.23293651; this version posted August 8, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license .

Table 6: M6-M6 Percent Reductions

Switching Profile	Q1 frequency (%)	Q2 frequency (%)	Q3 frequency (%)	Q4 frequency (%)
Ligand-Receptor	6.0 (66.7)	2.0 (22.2)	0.0 (0.0)	1.0 (11.1)
Receptor-Ligand	15.0 (71.4)	2.0 (9.5)	1.0 (4.8)	3.0 (14.3)
Ligand-Ligand	8.0 (44.4)	4.0 (22.2)	3.0 (16.7)	3.0 (16.7)

Q1: <25% reduction in MMD, Q2: 25% <x < 50% reduction in MMD, Q3: 50% <x < 75% reduction in MMD, Q4: >75% reduction in MMD

medRxiv preprint doi: https://doi.org/10.1101/2023.08.04.23293651; this version posted August 8, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license .

Figure 1: Flowchart of patients






Figure 2: Mean MMD's of switchers









Figure 3: Responders and non-responders' rates at month 3 and month 6 of patients with EM or CM on 3a: CGRP/L mAb and 3b: CGRP/R mAb during the first observational period.






Fig 4: Responders and non-responders' rates at month 3 and month 6 of patients with EM or CM on 4a after switching from CGRP/R-mAb to CGRP/L-mAb, 4b: from CGRP/L-mAb to CGRP/L-mAb 4c: Switched from CGRP/L-mAb to CGRP/R-mAb.

